Literature DB >> 27680737

[Management of axial spondyloarthritis].

U Kiltz1, X Baraliakos2, J Braun2.   

Abstract

The term spondyloarthritis (SpA) is now increasingly used to classify and diagnose patients who are characterized by inflammation in the axial skeleton and peripheral manifestations (arthritis and enthesitis). The management of SpA should be tailored according to the current manifestations of the disease, the disease activity and functional impairment. The current article focuses on diagnosis and therapy in patients with axial SpA. Diagnostic procedures are discussed in light of diagnostic utility and feasibility in daily routine care. Cornerstones of treatment in patients with axial SpA are a combination of regular exercise and pharmacological treatment options aiming at anti-inflammatory strategies.

Entities:  

Keywords:  Anti-inflammatory agents, non-steroidal; Biologics; Exercise; Sacroiliitis; Spondylitis, ankylosing

Mesh:

Substances:

Year:  2016        PMID: 27680737     DOI: 10.1007/s00108-016-0140-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

Review 2.  The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?

Authors:  Martin Rudwaleit; Muhammad A Khan; Joachim Sieper
Journal:  Arthritis Rheum       Date:  2005-04

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures].

Authors:  U Kiltz; W Mau; U Smolenski; U Repschläger; E Böhle; M Stemmer; U Oberschelp; E Schneider; B Swoboda; H Böhm; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.

Authors:  Ivette Essers; Sofia Ramiro; Carmen Stolwijk; Marc Blaauw; Robert Landewé; Désirée van der Heijde; Filip Van den Bosch; Maxime Dougados; Astrid van Tubergen
Journal:  Rheumatology (Oxford)       Date:  2014-09-17       Impact factor: 7.580

5.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

6.  Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.

Authors:  Martin Rudwaleit; Anke Metter; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2006-02

7.  Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic.

Authors:  L Heuft-Dorenbosch; R Landewé; R Weijers; H Houben; S van der Linden; P Jacobs; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-07-25       Impact factor: 19.103

8.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

9.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

10.  Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).

Authors:  Joachim Sieper; Joachim Listing; Denis Poddubnyy; In-Ho Song; Kay-Geert Hermann; Johanna Callhoff; Uta Syrbe; Jürgen Braun; Martin Rudwaleit
Journal:  Ann Rheum Dis       Date:  2015-08-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.